Stocks and Investing Stocks and Investing
Mon, November 5, 2018

David Risinger Upgraded (TEVA) to Buy and Held Target at $27 on, Nov 5th, 2018


Published on 2024-10-26 10:23:43 - WOPRAI, David Risinger
  Print publication without navigation


David Risinger of Morgan Stanley, Upgraded "Teva Pharmaceutical Industries Limited" (TEVA) to Buy and Held Target at $27 on, Nov 5th, 2018.

David has made no other calls on TEVA in the last 4 months.



There are 8 other peers that have a rating on TEVA. Out of the 8 peers that are also analyzing TEVA, 5 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Ami Fadia of "Leerink Swann" Upgraded from Sell to Hold on, Monday, October 1st, 2018
  • Tim Chiang of "BTIG" Upgraded from Strong Sell to Hold on, Monday, September 17th, 2018
  • Vamil Divan of "Credit Suisse" Maintained at Hold with Increased Target to $26 on, Monday, September 17th, 2018
  • Douglas Tsao of "Barclays" Maintained at Hold with Increased Target to $23 on, Monday, August 6th, 2018
  • Louise Chen of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $25 on, Monday, July 16th, 2018


These are the ratings of the 3 analyists that currently disagree with David


  • Jason Gerberry of "B of A Securities" Maintained at Sell with Increased Target to $20 on, Friday, November 2nd, 2018
  • Jami Rubin of "Goldman Sachs" Maintained at Strong Buy and Held Target at $30 on, Monday, October 1st, 2018
  • Irina Rivkind Koffler of "Mizuho" Maintained at Strong Buy with Increased Target to $29 on, Monday, September 17th, 2018
Contributing Sources